Bio­Car­dia un­veils in­ter­im da­ta that led it to stop PhI­II en­roll­ment of heart fail­ure stem cell ther­a­py

Bio­Car­dia dis­closed that its heart fail­ure stem cell ther­a­py failed to hit on all three mea­sures that com­prised the pri­ma­ry end­point of a Phase III study at an in­ter­im analy­sis.

In 102 pa­tients, there was no sta­tis­ti­cal­ly sig­nif­i­cant dif­fer­ence in rates of death, ma­jor car­dio­vas­cu­lar events and per­for­mance on the six-minute walk test (6MWT) at one year be­tween those who got Bio­Car­dia’s treat­ment and a sham, ac­cord­ing to Bio­Car­dia’s press re­lease Tues­day morn­ing.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.